{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:32:36Z","timestamp":1793251956133,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ophtha.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:07:15Z","timestamp":1789085235000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Common Anti-Inflammatory Medications with Reduced Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-7764","authenticated-orcid":false,"given":"Henry S.","family":"Bison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-8012","authenticated-orcid":false,"given":"Angela S.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3318-1131","authenticated-orcid":false,"given":"Martin","family":"Borissov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7940-7108","authenticated-orcid":false,"given":"Hee-Jae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-6762","authenticated-orcid":false,"given":"Yuji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-8600","authenticated-orcid":false,"given":"John T.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2026.09.005_bib2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.09.005_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(64)90008-X","article-title":"Diabetic retinopathy and rheumatoid arthritis","volume":"2","author":"Powell","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2026.09.005_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2026.09.005_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583687","article-title":"The role of inflammation in diabetic retinopathy","volume":"11","author":"Forrester","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ophtha.2026.09.005_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of fenofibrate on progression of diabetic retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ophtha.2026.09.005_bib7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2026.09.005_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00592-015-0759-3","article-title":"Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-\u03baB activity","volume":"53","author":"Garc\u00eda-Ram\u00edrez","year":"2016","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ophtha.2026.09.005_bib9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1046\/j.1365-2222.1999.00630.x","article-title":"Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549)","volume":"29","author":"Arnold","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ophtha.2026.09.005_bib10","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1096\/fj.01-0390rev","article-title":"Cyclooxygenase-independent actions of cyclooxygenase inhibitors","volume":"15","author":"Tegeder","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.ophtha.2026.09.005_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: inhibition of NF-\u03baB activity through induction of I\u03baB synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2026.09.005_bib12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ophtha.2026.09.005_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.ophtha.2026.09.005_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2026.09.005_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ophtha.2026.09.005_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ophtha.2016.11.034","article-title":"Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy","volume":"124","author":"Wykoff","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.09.005_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.09.005_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.diabres.2011.09.027","article-title":"The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers","volume":"95","author":"Samaropoulos","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2026.09.005_bib19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12020-020-02353-x","article-title":"Nitric oxide and TNF-\u03b1 are correlates of diabetic retinopathy independent of hs-CRP and HbA1c","volume":"69","author":"Khaloo","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.ophtha.2026.09.005_bib20","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1007\/s00417-024-06529-3","article-title":"Incidence of diabetic retinopathy in anti-TNF treated rheumatic disease patients with type 2 diabetes","volume":"262","author":"Baytaro\u011flu","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.09.005_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0161-6420(13)38010-5","article-title":"Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.09.005_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0161-6420(13)38009-9","article-title":"Early treatment diabetic retinopathy study design and baseline patient characteristics: ETDRS report number 7","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.09.005_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmj.4.5574.264","article-title":"Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis","volume":"4","author":"Boardman","year":"1967","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2026.09.005_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-\u03baB by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2026.09.005_bib25","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/rheumatology\/kev012","article-title":"Rheumatoid arthritis and the prevalence of diabetic retinopathy","volume":"54","author":"Bartels","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2026.09.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109175","article-title":"Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: a randomized controlled trial","volume":"39","author":"Rizk","year":"2025","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ophtha.2026.09.005_bib27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ophtha.2026.09.005_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ophtha.2026.03.023","article-title":"Toward an era of oculomics: association between baseline diabetic retinopathy severity and mortality risk in a SOURCE Consortium Cohort","volume":"133","author":"Lee","year":"2026","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026006780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026006780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:59:55Z","timestamp":1793249995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026006780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0161642026006780"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.09.005","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Common Anti-Inflammatory Medications with Reduced Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}